1. Opening remarks.................................................................Chair
2. Approval of May 6, 2020 P&T Committee Meeting minutes............Chair
3. Pharmacy program update.....................................................Alabama Medicaid
4. Oral presentations by manufacturers/manufacturers’ representatives
   (prior to each respective class review)
5. Pharmacotherapy class re-reviews.................................UMass Clinical Pharmacy Services
   • Calcitonin Gene-related Peptide (CGRP) Antagonists – AHFS 283212
   • Antiemetics, Antihistamines – AHFS 562208
   • Antiemetics, 5-HT3 Receptor Antagonists – AHFS 562220
   • Antiemetics, Neurokinin-1 Receptor Antagonists – AHFS 562232
   • Antiemetics, Miscellaneous – AHFS 562292
   • Centrally Acting Skeletal Muscle Relaxants – AHFS 122004
   • Direct-Acting Skeletal Muscle Relaxants – AHFS 122008
   • GABA-Derivative Skeletal Muscle Relaxants – AHFS 122012
   • Skeletal Muscle Relaxants, Miscellaneous – AHFS 122092
   • Opiate Agonists – AHFS 280808
   • Opiate Partial Agonists – AHFS 280812
   • Selective Serotonin Agonists – AHFS 283228
   • Proton-Pump Inhibitors – AHFS 562836
6. Results of voting announced..................................................Chair
7. Next meeting dates
   • November 4, 2020
   • February 3, 2021
   • May 5, 2021
8. Adjourn